<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120935</url>
  </required_header>
  <id_info>
    <org_study_id>IFOM-CPO003/2018/PO002</org_study_id>
    <nct_id>NCT04120935</nct_id>
  </id_info>
  <brief_title>A Master Protocol Empowering Precision Research in Colorectal Cancer</brief_title>
  <acronym>ALFAOMEGA</acronym>
  <official_title>A Master Protocol Empowering Precision Research in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IFOM, The FIRC Institute of Molecular Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IFOM, The FIRC Institute of Molecular Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between
      tumor and host cells in a cohort of CRC patients, with the aim of understanding how their
      outcomes can be significantly improved (e.g. reduction of their chance of recurrence and
      survival improval). This clinical resource for integrative clinical data and sample
      collection will allow the molecular story-telling of CRC metastatic spread along time and
      space and the selection of appropriate patients for experimentally-driven trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AlphaOmega is an observational study that will follow a stage-mixed cohort of at least 500
      patients through their course of treatments, until death or a minimum of 5 years. Patients
      will be longitudinally sampled and matched clinical data (including imaging) will be
      collected. Via a multi-tiered informed consensus process, AlphaOmega will also allow to
      develop companion diagnostics for molecular enrichment strategies in AIRC-driven
      proof-of-concept trials. To achieve the required level of 'experimental precision', patients
      will enter AlphaOmega at two different 'therapeutic checkpoints': i) prior to a surgical
      event or ii) prior to a systemic treatment. In the latter case patients with no previous
      lines of therapy for metastatic disease will be privileged.

      To optimize the enrollment of patients, the longitudinal collection of data/samples and their
      logistic management, AlphaOmega has been designed as a flexible infrastructure organized in
      TIERS for the stepwise comprehension of the biological processes that drive tumor evolution,
      and precisely:

        -  TIER1, Monitoring: the ability to follow CRC evolution under standard of care treatments
           and to define new evolution-linked biomarkers. This will be achieved through the
           collection of clinical data, imaging data, FFPE tissue and frozen plasma/PBMC.

        -  TIER2, Modelling: the ability to develop pertinent experimental models to study
           evolutionary mechanisms and define evolution-targeting therapeutic strategies. This will
           be achieved through the collection of Fresh Tissue, Whole Blood, Stools, Buccal Swabs
           and other fluids.

        -  TIER3, Linking: the ability to access data and samples of patients enrolled in
           proof-of-concept trials to prove the efficacy and study/understand resistance mechanisms
           of evolution-targeting therapies. This will be achieved by introducing the connection in
           the trial protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients longitudinally monitored</measure>
    <time_frame>6 months</time_frame>
    <description>- Number of recruited CRC cases in TIER1 with complete FFPE/clinical data match.
- Number of recruited CRC cases in TIER2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients triaged in proof-of-concept (POC) clinical trials</measure>
    <time_frame>6 months</time_frame>
    <description>Number of CRC cases recruited in TIER3.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of new prognostic and predictive biomarkers</measure>
    <time_frame>6 months</time_frame>
    <description>- Number of identified/validated new prognostic markers
- Number of identified/validated new predictive markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of new prognostic and predictive biomarkers with clinical outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>- Correlation between identified biomarkers with therapies response rates (RR).
- Correlation between identified biomarkers with progression-free survival (PFS).
- Correlation between identified biomarkers with overall survival (OS).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort of CRC patients</arm_group_label>
    <description>Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Prospective Observation of standard clinical practice.</description>
    <arm_group_label>Cohort of CRC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  FFPE Tissue

        -  Fresh Tissue (tumor and normal)

        -  Plasma

        -  PBMC

        -  Whole Blood

        -  Stools

        -  Buccal Swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. TIER1 written Informed consent.

          2. Patients ≥18 years of age.

          3. Previous diagnosis of colorectal cancer, or a strong suspicion of CRC based on
             clinical and radiological findings.

          4. In patients with previous diagnosis of CRC availability of diagnostic Formalin-Fixed,
             Paraffin Embedded (FFPE) blocks (surgical resection and/or tumor biopsies), or at
             least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.

          5. ECOG Performance status &lt; 2.

        Exclusion Criteria:

          1. Any other current malignancy or malignancy diagnosed or relapsed within the past 5
             years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ
             cervical cancer)

          2. Patient unable to comply with the study protocol owing to psychological, social or
             geographical reasons.

          3. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus
             (HCV) or syphilis infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Silvia Marsoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFOM, The FIRC Institute of Molecular Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Luraghi, PhD</last_name>
    <phone>+3902574303799</phone>
    <email>paolo.luraghi@ifom.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luca Lazzari, PhD</last_name>
    <phone>+3902574303799</phone>
    <email>luca.lazzari@ifom.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII Oncologia Medica</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefania Mosconi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs, Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Pietrantonio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milan</city>
        <state>Mi</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Siena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Lonardi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefania Sciallero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara Montagut, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall D'Hebron Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Tabernero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrés Cervantes, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

